Mesoblast Limited Sponsored ADR (MESO)
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast H2 Earnings Call Highlights
Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust early revenue growth. Ryoncil's regulatory, reimbursement, and manufacturing precedents de-risk MESO's broader mesenchymal lineage platform and future label expansions. Cash burn has decreased, non-dilutive funding strengthens the balance sheet, and pipeline progress supports a platform premium valuation.
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and advances rapidly into a registrational DMD trial. Ryoncil's DMD opportunity is underappreciated, with a modeled $2B peak sales and $1.18B risk-adjusted NPV, enabled by FDA confidence in its safety profile. SR-aGVHD remains a niche but high-margin market, with Ryoncil nearing $100M in sales and strong launch adoption, though adult expansion faces competition.
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
Mesoblast (MESO) is demonstrating rapid revenue growth post-Ryoncil launch, with Q4 gross sales up 60% sequentially and strong market penetration. MESO's balance sheet is fortified by $130M cash and a new $125M non-dilutive credit facility, reducing dilution risk and supporting pipeline investment. The near-term catalyst is a pivotal adult SR-aGvHD trial, which could triple the addressable market if successful, leveraging existing pediatric infrastructure.
Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
